鱼跃医疗
(002223)
| 流通市值:264.73亿 | | | 总市值:281.78亿 |
| 流通股本:9.34亿 | | | 总股本:9.95亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,611,409,739.05 | 4,569,315,559.46 | 2,370,366,154.18 | 7,955,022,614.76 |
| 营业收入 | 6,611,409,739.05 | 4,569,315,559.46 | 2,370,366,154.18 | 7,955,022,614.76 |
| 二、营业总成本 | 5,400,804,085.85 | 3,668,138,104.59 | 1,866,982,526.48 | 6,616,589,598.1 |
| 营业成本 | 3,314,300,267.75 | 2,293,672,533.98 | 1,180,164,309.42 | 3,930,042,261.81 |
| 税金及附加 | 62,996,725.26 | 42,450,416.55 | 22,326,740.29 | 76,397,429.33 |
| 销售费用 | 1,278,923,727.86 | 834,398,757.01 | 402,815,941.57 | 1,763,462,079.41 |
| 管理费用 | 348,658,392.14 | 226,354,161.08 | 110,547,207.98 | 475,517,451.17 |
| 研发费用 | 446,980,926.22 | 306,296,171.98 | 158,685,705.74 | 570,145,985.28 |
| 财务费用 | -51,055,953.38 | -35,033,936.01 | -7,557,378.52 | -198,975,608.9 |
| 其中:利息费用 | - | - | - | 5,997,356.94 |
| 其中:利息收入 | 173,308,242.87 | 119,864,759.74 | 48,107,693.6 | 249,182,104.77 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 0 | - | - | - |
| 加:投资收益 | 22,296,760.44 | 18,236,442.79 | 2,271,021.41 | 34,149,903.34 |
| 资产处置收益 | -236,451.13 | -236,451.13 | -371,380.78 | 1,281,395.38 |
| 资产减值损失(新) | 1,287,726.86 | 1,557,761.33 | 141,611.71 | -29,634,938.18 |
| 信用减值损失(新) | -35,483,829.55 | -29,758,881.08 | -30,246,861.9 | -3,837,303.57 |
| 其他收益 | 87,554,316.83 | 67,163,578.04 | 26,114,710.86 | 359,928,878.71 |
| 营业利润平衡项目 | 0 | - | 0 | 0 |
| 四、营业利润 | 1,286,024,176.65 | 958,139,904.82 | 501,292,729 | 1,700,320,952.34 |
| 加:营业外收入 | 16,584,835.25 | 15,120,372.76 | 445,484.44 | 26,290,665.47 |
| 减:营业外支出 | 6,268,133.78 | 1,655,369.29 | 336,039.97 | 42,119,422.16 |
| 利润总额平衡项目 | 0 | - | 0 | 0 |
| 五、利润总额 | 1,296,340,878.12 | 971,604,908.29 | 501,402,173.47 | 1,684,492,195.65 |
| 减:所得税费用 | 157,079,489.89 | 123,735,865.06 | 72,190,934.45 | 200,355,944.78 |
| 六、净利润 | 1,139,261,388.23 | 847,869,043.23 | 429,211,239.02 | 1,484,136,250.87 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,139,261,388.23 | 847,869,043.23 | 429,211,239.02 | 1,484,136,250.87 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,131,297,210.38 | 842,813,546.32 | 428,328,475.91 | 1,481,794,880.13 |
| 少数股东损益 | 7,964,177.85 | 5,055,496.91 | 882,763.11 | 2,341,370.74 |
| 扣除非经常损益后的净利润 | 1,037,380,297.98 | 761,227,088.92 | 410,114,212.99 | 1,168,613,796.79 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.14 | 0.84 | 0.43 | 1.48 |
| (二)稀释每股收益 | 1.14 | 0.84 | 0.43 | 1.48 |
| 八、其他综合收益 | -58,079,071.82 | -28,429,681.41 | -21,770,602.63 | 98,208,788.57 |
| 归属于母公司股东的其他综合收益 | -55,863,723.66 | -26,871,694.91 | -20,954,061.59 | 95,069,868.13 |
| 九、综合收益总额 | 1,081,182,316.41 | 819,439,361.82 | 407,440,636.39 | 1,582,345,039.44 |
| 归属于母公司股东的综合收益总额 | 1,075,433,486.72 | 815,941,851.41 | 407,374,414.32 | 1,576,864,748.26 |
| 归属于少数股东的综合收益总额 | 5,748,829.69 | 3,497,510.41 | 66,222.07 | 5,480,291.18 |
| 公告日期 | 2026-10-24 | 2026-08-22 | 2026-04-25 | 2026-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |